Thank you, Kevin. Good morning, and welcome everyone. At this time, I would like to remind our listeners that remarks made during this webcast may state management's intentions, beliefs, expectations, or future projections. These are forward-looking statements and involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the safe harbor provisions of the federal securities laws and are based on Moleculin’s current expectations and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results to differ materially from these contemplated by such forward-looking statements are discussed in the periodic reports, Moleculin files with the Securities and Exchange Commission. These documents are available in the Investors section of the company's website and on the Securities and Exchange Commission's website. We encourage you to review these documents carefully. Additionally, certain information contained in this webcast relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company's own estimates and research. While the company believes these third-party sources to be reliable as of the date of this presentation, it does not independently verify and makes no representation as to the adequacy, fairness, accuracy or completeness of or that any independent source has verifying any information obtained from third party source. Any data discussed regarding clinical trials and progress are considered preliminary and subject to change. Joining us on the call today from the Moleculin’s management team are Walter Klemp, Chairman and Chief Executive Officer; Dr. John Paul Waymack, Senior Chief Medical Officer; and Jonathan Foster, Executive Vice President and Chief Financial Officer. I would now like to turn the call over to Mr. Klemp, Chairman and CEO. Wally, please proceed.

Thanks, Jenene, and thanks to everyone on today's call for your interest in Moleculin. We reiterated our commitment on our last two quarterly calls that 2023 would be our year of data. And now the data from our priority pipeline programs are coming into view. We've now completed the Phase 1B portion of our MB-106 trial. That's the AML trial in Europe studying the combination of Annamycin with Cytarabine or Ara-C. Importantly, that means we've now established our Phase 2 dose and have commenced Phase 2 recruitment. In the meantime, the preliminary CR rate or complete response rate for the Phase 1B portion of our AML program looks to be 33%. And as our senior CMO, Dr. Paul Waymack will discuss, that's already well above the benchmark used for approval in the class of patients we're targeting. In our other lead indication of soft tissue sarcoma, we're now seeing 73% of subjects exhibiting stable disease after two cycles of treatment. Again, this is above expectations at this stage of STS lung metastases and indicative of an encouraging efficacy signal. As always, I should stress that these data are preliminary and subject to change, but so far we are very encouraged by what we're seeing. So when we look at the milestones we've set out for this year with Annamycin, we've already delivered on the first three, and we have more to come. Specifically, we expect to be announcing Phase 2 data for AML and more Phase 2 data for STS, which we intend to do with each quarterly and year-end call. And let's not forget that there's ongoing development work in our other two technologies, and that should be generating news flow yet this year. But we know that the main focus for most investors is on Annamycin, and here to discuss that in more detail is our Senior Chief Medical Officer, Dr. Paul Waymack. Paul?

Thank you, Wally. I'll get right into it. For our lead compound, Annamycin, we continue to generate favorable clinical data for our ongoing Phase 1B/2 clinical trials of Annamycin in patients with soft tissue sarcoma with lung metastases, and in patients with acute myelogenous leukemia, that is AML. We believe we are positioned to complete both trials early next year. Our soft tissue sarcoma trial, MB-107, is a combined Phase 1B and Phase 2 trial. For the combined Phase 1B and 2 components, we have enrolled and treated a total of 26 patients with at least two cycles of therapy. I should note that completion of two cycles occurs every six weeks and is immediately followed with a CT scan to assess tumor status. Now among these 26 patients, we have achieved a 73% rate of stable disease. And similar results have been seen in the 15 patients who are being treated in the Phase 2 component of the study, wherein we have a 67% rate of stable disease after the first two cycles. During the remainder of the second half of this year, we anticipate reporting additional interim data, including top line progression-free survival data and overall survival data. In our ongoing Phase 1B/2 MB-106 clinical trial, which is in patients with refractory and relapsed AML, we have had six patients complete the dose escalation Phase 1B portion of the study. This 1B portion of study has identified 230 milligrams per meter square as the dose to be used in to Phase 2 portions of the study, and we are now enrolling patients in the Phase 2 portion of the study. We should note that the Phase 2 portion of the study is enrolling not only patients with refractory and relapsed leukemia, but also patients for whom Annamycin will be the first-line therapy. We were not only pleased that the Phase 1B portion of the study identified the dose of Annamycin to be used in the Phase 2 part of the study, but that has also resulted in two of the six patients achieving a CR or a CRi. That is a 33% CR plus CRi success rate. Now, again, we want to stress that these data are preliminary and subject to change, but I would also add for perspective that we have seen recent new drug approvals in AML based on lower levels of complete response. So we are very encouraged by the data so far. Finally, let me note that we continue to monitor closely for evidence of any cardiac toxicity in all patients treated with Annamycin. And yet, we have still not had a single patient in any of our trials exhibit any signs, symptoms, lab results, EKG results or imaging results that have shown evidence of heart damage. During the second half of this year, we anticipate presenting the study report from our prior successful MB-105 monotherapy with Annamycin in patients with AML study. We also anticipate presenting updates on our ongoing 106 study. I am very encouraged about what we are seeing and for the potential for Annamycin for both of our lead indications. Moving on to our Immune/Transcription Modulator. We continue to make progress in creating an intravenous formulation of our 1066 drug. Simultaneously, we are having discussions with multiple academic institutions to initiate investigator sponsored clinical trials or programs for the treatment of adult and pediatric tumors of the brain. During the second half of this year, we hope to report top-line results from an investigator-initiated Phase 1 study in pediatric brain tumors. We will also continue to seek external funding opportunities for investigator-initiated clinical trials and we'll provide updates on our IV formulation development. Regarding our 1122 glycosylation inhibitor, we have opened an IND to initiate a Phase 1 study for the treatment of glioblastomas. That is brain tumors, brain cancers. We have also been granted orphan drug designation from FDA for the treatment of glioblastoma-type brain tumors. During the second half of this year, we hope to report preliminary findings of the National Institute of Health and under the NIH funded animal testing in studies with the tacaribe arenavirus, and we will continue to seek external funding opportunities for an investigator initiated clinical trial. Jon, onto you.

Thanks, Paul. Based on our current Phase 1B/2 activities, and ramping up for future programs, our $32 million of cash on hand at the end of Q2 should take us into the third quarter of 2024. The planned funded activities include our current trials and also beginning Phase 3 tac studies and other preparations for future possible AML and STS trials with Annamycin. We continue with our financial focus on advancing Annamycin in clinical studies and finding an IV formulation for WP1066. R&D expense declined slightly in the second quarter versus the prior year quarter as we were running three clinical trials MB-106, MB-107 and MB-301 last year. Now, we are focused on MB-106 and MB-107 and moving Annamycin forward in future clinical studies. G&A expense decreased as a result of reduced legal expenses. In our last shareholder meeting process, we spoke with numerous shareholders and they voiced their concern over potential naked short selling and stock price manipulation. We heard you, we are aligned and we agree that we should do everything possible to guard against this. Recently, we engaged share intelligence services to monitor trading activity in our stock, stock ownership and significant movement of ownership to provide us with more knowledge on our trading activity. Wally?

Thanks, Jon. Well, I'm sure from our discussion today it's clear that we are laser focused on clinical execution right now. And the payoff should be in important data readouts over the coming quarters. These data will play two critical roles. Continuing to communicate efficacy in both STS and AML, as well as informing the pivotal clinical trial designs that we will begin negotiating with regulatory authorities. And as Jon mentioned, we are in a solid position of having sufficient capital to reach what we believe are key data and regulatory milestones along the way. But perhaps most importantly for shareholders, we believe the data rolling in over the balance of the year will begin to address the disconnect we see between our current share price and what we believe is the real potential value of Moleculin. Well, Jenene, that covers our prepared slides for today's call, but we'd be happy to answer any questions people may have.

Thank you, Wally. Kevin, please proceed.

Certainly. We will now start the question-and-answer session. Our first question today is from Jonathan Aschoff from ROTH MKM. Your line is now live.

Thank you. Good morning, everyone. Jon, I have a quick question for you. Is the current R&D run rate sustainable, or is it just temporarily low like it was last year?

It should be low this quarter and gradually increasing as we move into the fourth quarter and the first quarter of next year as we prepare for the future clinical trials as I've discussed. We'll have another batch of Annamycin being produced. So that's where we get to the $32 million taking us into the third quarter of next year.

Thank you. In my last quarterly note, I provided more specific timing for upcoming catalysts than I do now. I was wondering if you could clarify that. Are you slowing down to save money, or is there another reason for the change?

Let me start by addressing that, though you may want to add your thoughts on our decisions regarding disclosures. We do not see anything slowing down. I believe some of the progress we aim to achieve for the rest of the year involves engaging with the FDA. As you know, Jonathan, timing with regulatory authorities is uncertain. We want to ensure everyone understands that we will begin negotiations with regulatory bodies, but we prefer not to be too specific about when we will receive feedback, as committing to a timeline could lead to inaccuracies. We are seeing strong recruitment in both trials and are maintaining our timelines, but we need to acknowledge that we cannot predict regulatory discussions with precision.

That's fair. And lastly, why do you think the SD rate was higher when you included the 31 evaluable patients at different doses? This is STS, LM, then with just the 15 evaluable patients at the recommended Phase 2 dose? So I was just curious why that SD rate was kind of flipped versus what I'd expect?

So, Jon, you've been closest to cringing all those numbers on a regular basis. You want to tackle that one?

Yeah. And I think Paul can add in here as well. When you look at the time from initial diagnosis of lung metastasis, we're getting very tired patients. And so you're seeing a little difference from the standpoint of the time from initial diagnosis to the time when they enter in our trial. The last time I looked at it, the median time from initial diagnosis of lung metastasis appears to be around 20 months. So that's very tired patients from a lung metastasis standpoint. Paul, you want to add some color?

I'll just add lack of color and play statistician and say that when the numbers are 67% and 73%, unless you got a 10,000 patient study, those numbers statistically are just about the same. So I would not put any great emphasis on 67% versus 73% except those are both, in our opinion, really good numbers to have when you look at the literature.

Those are very fair answers. Thank, guys.

Thanks, Jonathan.

Thank you. Next question is coming from Jeff Jones from Oppenheimer. Your line is now live.

Hi, everyone. Congratulations on the quarter. Thank you for taking my question. You mentioned updating on data and presenting it; is there a plan to present at a conference, or will this be included in your typical quarterly updates?

Our focus here was primarily on the quarterly updates. However, we are certainly planning to present at the upcoming ASH and other important meetings like CTOS. The data will be captivating for those conferences, and we have team members ready to present. It's important for this call to clarify that during our quarterly calls, we will provide a very comprehensive clinical update.

Great. I appreciate that, Wally. In terms of the MB-107 STS lung mets study, with the patients being dosed at the RP2D, I believe you have 15 patients evaluable. Were there any PRs or CRs, or do you anticipate sharing waterfall or swimmer plots to provide more visibility on the individual patients?

So, Paul, do you want to address this question?

Thank you. First, when we mention that the data are preliminary, that's certainly the case because, at the recommended Phase 2 dose, we still have many patients who are ongoing and have not yet experienced disease progression. Some patients have not even had their initial six-week follow-up scans yet. Therefore, these results are very preliminary. We have not observed any patient with an improvement beyond stable disease. However, given that these patients are generally in the fourth line of therapy, we are not surprised and are quite pleased that we can report that 67% to 73% of them have stable disease at the time of the initial evaluation, especially considering what the literature indicates would be expected from this patient population.

Great. Thank you, guys.

Thank you. We’ve reached the end of our question-and-answer session. I'd like to turn the floor back over for any further closing comments.

Thank you. Again, thanks everybody. Obviously, as we've said in multiple conference calls before this, the data is coming in. And so, it's actually a pretty exciting time for us and we're really looking forward to these, especially these next two quarters, just because of the timing of the additional data that's going to be coming in. So please stay tuned. We can't wait to report more data. Have a great day.

Thank you. That does conclude today's teleconference and webcast. You may disconnect your line at this time and have a wonderful day. We thank you for your participation today.